Weiqiang Medical's Thoracic Aortic Stent System Receives NMPA Approval for Market Launch

Recently, the National Medical Products Administration (NMPA) has approved the registration of the innovative product "Thoracic Aortic Stent System" produced by Hangzhou Wei Qiang Medical Technology Co., Ltd. after review.

This product consists of a proximal thoracic aorta covered stent graft system and a distal thoracic aorta bare stent system. The proximal thoracic aorta covered stent graft system seals the proximal entry tear of Type B dissection, promoting thrombosis within the false lumen; the distal thoracic aorta bare stent system dilates the true lumen of the distal descending aorta, facilitating aortic true lumen remodeling. The structural design of the stents ensures excellent flexibility along with certain radial and axial support. The thoracic aorta covered stent and the thoracic aorta bare stent are preloaded in their respective delivery systems, the design of which ensures stability during deployment and precise positioning of the stent.

Aortic dissection has an acute onset, rapid progression, and high mortality rate. Stent products have become the main method for endovascular interventional treatment of this disease. This product is suitable for treating Stanford Type B dissections, with a proximal stent anchoring zone length ≥15mm, and the lesion meets one of the following conditions: 1. Presence of a distal tear, necessitating treatment of the distal lesion; 2. The dissection involves a wide range with distal true lumen collapse; 3. The dissection is accompanied by distal perfusion impairment.